| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
111, Inc. American Depositary Shares$4.29
+0.59 (+15.95%)
Market Cap
56.88 M
EPS
-1.06
P/E Ratio
-6.2 $
Value Trade
149.20 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
41.26 K
52 Week Range
2.48 - 11.17
% held by Insiders
1.82 %
% held by Institutions
1.21 %
Enterprise Value
131.71 M
Total Shares
5.04 M
Short %
0.12 %
Float Shares
4.95 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in YI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
111, Inc. American Depositary Shares (YI) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
YI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
YI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
YI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
YI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
YI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-YI
Jun 4, 2026Inc. Announces First Quarter 2026 Unaudited Financial Results Continuing Transition toward a More Asset-Light and Operationally Efficient Business Model Net Revenue of Promotional Products (1) Increased by 70.2% and Gros
111, Inc. reported its unaudited financial results for Q1 2026, highlighting a strategic transition towards a more asset-light and efficient business model. The company experienced a 70.2% increase in net revenue from promotional products, while total marketplace service revenue rose by 24.7% year-over-year. Despite these positives, overall revenue fell by 33.1%, leading to reduced gross profits and sustained net losses compared to the same quarter last year. The company is positioned for growth through technology integration and improved operational efficiency.
Read more →-YI
Apr 9, 2026Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results Continuing Transition to an Asset-Light Business Model to Improve Overall Efficiency Delivered Non-GAAP Operating Profitability in Both Q4'25 and FY'25
111, Inc. reported its financial results for the fourth quarter and fiscal year 2025, highlighting a successful transition towards an asset-light business model. The company achieved non-GAAP operating profitability for both the quarter and the full year, despite a revenue decline of 12.8% for FY'25 due to structural optimization efforts. The divestiture of subsidiaries allowed 111 to strengthen its platform and increase its marketing capabilities, notably reflected in a significant rise in sales for its flagship product 'Cravit'. Overall, the results show progress in margin expansion and a solid foundation for future growth.
Read more →-YI
Dec 17, 2025Inc. Announces Third Quarter 2025 Unaudited Financial Results Transition from An Asset-Heavy Business Model to An Asset-Light Business Model Achieved Quarterly Non-GAAP Net Profitability Maintained Non-GAAP Operational P
111, Inc. reported its third quarter 2025 financial results, highlighting a strategic transition to an asset-light business model. The company achieved non-GAAP operational profitability for the third consecutive quarter despite a challenging macroeconomic environment. However, it faced a 16.7% decrease in revenues year-over-year and reported a loss from operations. The divestiture of three subsidiaries aims to strengthen liquidity while maintaining service capabilities through partnerships.
Read more →-YI
Sep 17, 2025Inc. Announces Second Quarter 2025 Unaudited Financial Results Maintained Quarterly Operational Profitability Operating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoY Maintained Positive Operating Cas
111, Inc. has reported its unaudited financial results for the second quarter of 2025, indicating a resilient business model amidst a challenging macroeconomic environment. While the company maintained operational profitability and a positive cash flow, revenues decreased by 6.4% compared to the previous year. Key highlights include significant growth in marketing promotional product sales and an expansion of fulfillment centers. However, the company also faced a decline in segment profits and an increase in non-GAAP net loss year-over-year.
Read more →-YI
Jun 19, 2025Inc. Announces First Quarter 2025 Unaudited Financial Results Maintained Quarterly Operational Profitability Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY Maintained Quarterly Positive Oper
111, Inc. announced its unaudited financial results for Q1 2025, reporting stable net revenues of RMB 3.5 billion amidst challenging market conditions. The company achieved operational profitability and successfully reduced operating expenses, highlighting its focus on efficiency. However, gross segment profit saw a year-over-year decline of 6.4%, and both B2C revenues and net loss attributable to shareholders increased compared to the previous year. The company remains committed to leveraging technology to enhance its operations and capture opportunities in the market.
Read more →-YI
Mar 20, 2025Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results Achieved First-Ever Annual Operating Profit Bottom Line Improved by RMB332.7 Million YoY in 2024 Operating Expenses as a Percentage of Revenues Decreas
111, Inc. reported its financial results for the fourth quarter and fiscal year of 2024, highlighting its first-ever annual operational profit of RMB2.1 million. Despite a slight decline in revenues, the company improved its operational efficiency, lowering total operating expenses significantly. The CEO emphasized the resilience of their business model amid a challenging macroeconomic environment and ongoing healthcare reforms. Looking ahead, 111, Inc. plans to invest further in AI and digital technologies to enhance its competitive position in the evolving healthcare landscape.
Read more →-YI
Feb 11, 2025Inc. Regains Compliance with NASDAQ Requirement SHANGHAI
111, Inc. has announced that it has regained compliance with NASDAQ Listing Rule 5450(a)(1) after the closing bid price of its American Depositary Shares remained above $1.00 for ten consecutive business days. This determination was communicated by NASDAQ on February 10, 2025, and the matter is now considered closed. The company, which operates a tech-enabled healthcare platform in China, is focused on reshaping the healthcare value chain while providing better access to pharmaceutical products and services.
Read more →-YI
Jan 8, 2025Inc. Announces ADS Ratio Change SHANGHAI
111, Inc. has announced a change in the ratio of its American Depositary Shares (ADS) to Class A ordinary shares, transitioning from one ADS representing two shares to one representing twenty. This change, which functions similarly to a one-for-ten reverse ADS split, is slated to take effect on January 24, 2025. While it is anticipated that the ADS price will increase proportionally following the change, the company has indicated uncertainty regarding achieving a specific price point. The company emphasizes that no action is needed from ADS holders for this change to be implemented.
Read more →-YI
Nov 27, 2024Inc. Announces Third Quarter 2024 Unaudited Financial Results Maintained Operational Profitability for the Third Consecutive Quarter Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY Held Posi
111, Inc. reported its unaudited financial results for Q3 2024, highlighting operational profitability for the third consecutive quarter with income from operations at RMB2.4 million. Despite a 1.8% decrease in gross revenues and significant declines in B2C revenues, the company successfully reduced operating expenses and emphasized continued investment in technology and infrastructure. The CEO remarked on the resilience of the business model amid macroeconomic challenges and expressed confidence in long-term growth opportunities within the pharmaceutical sector.
Read more →-YI
Nov 4, 2024Inc. Announces Change to Board of Directors SHANGHAI
111, Inc. announced a change to its Board of Directors, with Dr. Leon Lian Yong Chen resigning for personal reasons. The company appointed Mr. Yang 'Luke' Chen as a new director, effective immediately. Dr. Chen has been recognized for his valuable contributions since joining the board in 2019. Mr. Gang Yu expressed optimism regarding Mr. Yang's financial expertise and its importance for the company's future initiatives.
Read more →-YI
Aug 29, 2024Inc. Announces Second Quarter 2024 Unaudited Financial Results Maintained Operational Profitability for the Second Consecutive Quarter Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY Held Po
111, Inc. announced its second quarter 2024 financial results, reporting operational profitability for the second consecutive quarter despite a tough macroeconomic environment. The company achieved income from operations of RMB3.3 million, a significant recovery from a loss the previous year. Although revenues decreased by 1.5%, operational efficiency improved with reduced expenses. Furthermore, the company highlighted technological advancements and strategic partnerships aimed at market growth.
Read more →-YI
May 23, 2024Inc. Announces First Quarter 2024 Unaudited Financial Results Turned to Quarterly Operational Profitability for the First Time Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8% Achieve
111, Inc. has reported its first quarter financial results for 2024, marking a significant milestone with operational profitability achieved for the first time. The company's income from operations reached RMB3.7 million, a positive shift from the prior year's operational loss. Despite a decrease in overall revenue due to a high baseline from the previous year during the pandemic, the company has demonstrated substantial growth in non-GAAP income from operations. By optimizing expenses and enhancing operational efficiency, 111, Inc. is well-positioned for future growth opportunities in the tech-enabled healthcare sector.
Read more →-YI
Mar 21, 2024Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results SHANGHAI
111, Inc. announced its financial results for the fourth quarter and fiscal year ending December 31, 2023. The company reported a slight decrease in net revenues for the fourth quarter, alongside a notable drop in gross segment profit. Despite these challenges, the company achieved overall revenue growth for the fiscal year and has made strides in operational efficiency and digital innovation within the healthcare sector. Significant accolades for their efforts in technology integration highlight 111, Inc.'s proactive approach in enhancing operational capabilities.
Read more →-YI
Feb 27, 2024Announces Receipt of Withdrawal of Going Private Proposal 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and h
111, Inc. (NASDAQ: YI) has announced the withdrawal of a going private proposal from a consortium led by its co-founders. The consortium originally submitted two proposals in September and October 2022 but has decided to terminate negotiations with the company's board. This development raises questions about the company's strategic direction and investor confidence moving forward.
Read more →-YI
Nov 30, 2023Inc. Announces Third Quarter 2023 Unaudited Financial Results SHANGHAI
111, Inc. announced its unaudited financial results for Q3 2023, reporting a 9.5% increase in net revenue to RMB3.7 billion. Despite challenges in the macroeconomy and the retail pharmacy sector, the company's operational loss decreased compared to the previous year. They have achieved operational efficiency improvements, reducing expenses as a percentage of revenues. However, the gross segment profit declined 5.6%, highlighting ongoing challenges in specific areas.
Read more →-YI
Aug 24, 2023Inc. Announces Second Quarter 2023 Unaudited Financial Results SHANGHAI
111, Inc. reported its unaudited financial results for Q2 2023, highlighting a 14.5% increase in net revenue compared to the same quarter last year. The company's operational loss was reduced considerably, demonstrating improved financial performance after years of consistent growth. Significant advancements in digital technology and partnerships, particularly with Tencent, are set to enhance service delivery and operational efficiency. Overall, the company remains optimistic about maintaining its growth trajectory in the competitive healthcare sector in China.
Read more →-YI
Jun 15, 2023Inc. Announces First Quarter 2023 Unaudited Financial Results SHANGHAI
111, Inc. reported its unaudited financial results for the first quarter of 2023, showcasing significant growth with a 23.9% rise in net revenue to RMB3.7 billion. The company also marked its 19th consecutive quarter of year-over-year growth. Notably, for the first time, Non-GAAP income from operations turned positive, indicating a successful operational turnaround. However, challenges persist in the B2C segment, where service revenue has seen a drastic decline of 40.9%. Despite a reported operational loss, overall efficiency has improved significantly, showcasing the company's potential for future profitability.
Read more →-YI
Mar 23, 2023Inc. Announces Fourth Quarter and Fiscal Year 2022 Financial Results SHANGHAI
111, Inc. reported its financial results for the fourth quarter and fiscal year 2022, showing a 19.9% increase in net revenue to RMB 4.1 billion. The company also achieved positive operating cash flow for the second consecutive quarter and narrowed its non-GAAP loss from operations. Despite the impact of lockdowns, 111, Inc. managed to achieve growth and improve its margin profile. However, the B2C segment experienced a decline, highlighting some ongoing challenges within the company's overall performance.
Read more →-YI
Dec 1, 2022Inc. Announces Third Quarter 2022 Unaudited Financial Results SHANGHAI
111, Inc. Announces Third Quarter 2022 Unaudited SHANGHAI, December 1, 2022 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in Ch
Read more →-YI
Sep 23, 2022Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee SHANGHAI
Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Spec
Read more →-YI
Sep 9, 2022Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company SHANGHAI
Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company 9, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that its Board of Directors (the "Board") has
Read more →-YI
Aug 25, 2022Inc. Announces Second Quarter 2022 Unaudited Financial Results SHANGHAI
111, Inc. Announces Second Quarter 2022 Unaudited SHANGHAI, August 25, 2022 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in Ch
Read more →-YI
Jun 16, 2022Inc. Announces First Quarter 2022 Unaudited Financial Results SHANGHAI
First Quarter 2022 Unaudited Financial Results 2022 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its
Read more →-YI
May 5, 2022Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act SHANGHAI
111, Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act SHANGHAI, May 5, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that on May 4th, 20
Read more →-YI
Mar 17, 2022Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results SHANGHAI
111, Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results 17, 2022 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare service
Read more →-YI
Nov 19, 2021Inc. Announces Third Quarter 2021 Unaudited Financial Results SHANGHAI
111, Inc. Announces Third Quarter 2021 Unaudited SHANGHAI, November 19, 2021 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in C
Read more →-YI
Sep 7, 2021Inc. Announces $10 Million Share Repurchase Program SHANGHAI, Sept.7, 2021 /PRNewswire/ -- 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecti
Inc. Announces $10 Million Share Repurchase Program 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announce
Read more →-YI
Aug 27, 2021Inc. Announces Second Quarter 2021 Unaudited Financial Results SHANGHAI
Second Quarter 2021 Unaudited Financial Results SHANGHAI, August 27, 2021 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in Chin
Read more →-YI
May 19, 2021Inc. Announces First Quarter 2021 Unaudited Financial Results SHANGHAI
First Quarter 2021 Unaudited Financial Results 2021 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its
Read more →-YI
Mar 18, 2021Inc. Announces Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results SHANGHAI
111, Inc. Announces Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results March 18, 2021 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), "), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine an
Read more →-YI
Dec 22, 2020Inc. Announces Additional Round of New Capital Injection Led by Esteemed List of Technology Investment Firms SHANGHAI
Announces Additional Round of New Capital Injection by Esteemed List of Technology Investment Firms December 22, 2020 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading digital healthcare platform company committed to digitally connecting patients with m
Read more →-YI
Nov 19, 2020Inc. Announces Third Quarter 2020 Unaudited Financial Results SHANGHAI
111, Inc. Announces Third Quarter 2020 Unaudited Financial Results November 19, 2020 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading digital healthcare platform committed to digitally connecting patients with medicine and healthcare services in China,
Read more →-YI
Aug 20, 2020Inc. Announces New Capital Injection and Strategic Plan to Expand Access to China's Capital Markets Completion of new capital injection in principal subsidiary Yao Fang Shanghai Initiation to list shares of principal sub
New Capital Injection and Strategic Plan to Expand Access to China's SHANGHAI, August 20, 2020 /PRNewswire/ - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a company dedicated to digitally connecting patients with drugs and healthcare services in China, today announced the
Read more →-YI
May 21, 2020Inc. Announces First Quarter 2020 Unaudited Financial Results SHANGHAI
Announces First Quarter 2020 Unaudited Financial Results May 21, 2020 (PR Newswire) - 111, Inc. ("111" or the "Company") (NASDAQ: YI), a Company dedicated to digitally connecting patients with drugs and healthcare services in China, today announced its unaudited financial resul
Read more →-YI
Mar 12, 2020Inc. Announces Fourth Quarter and Fiscal Year 2019 Unaudited Financial Results SHANGHAI, CHINA
111, Inc. Announces Fourth Quarter and Fiscal Year 2019 Unaudited Financial Results SHANGHAI, CHINA - March 12, 2020 - 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial res
Read more →-YI
Nov 15, 2019Inc. Announces Third Quarter 2019 Unaudited Financial Results SHANGHAI, CHINA November 14 , 2019 - 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, toda
111, Inc. Announces Third Quarter 2019 Unaudited Financial Results SHANGHAI, CHINA November 14, 2019 - 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial results for the thi
Read more →-YI
Aug 15, 2019Inc. Announces Second Quarter 2019 Unaudited Financial Results and US$10 Million Share Repurchase Program SHANGHAI
111, Inc. Announces Second Quarter 2019 Unaudited Financial Results and US$10 Million Share Repurchase Program SHANGHAI, Aug. 15, 2019 /PRNewswire/ 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announc
Read more →-YI
May 16, 2019Announces Changes to its Board of Directors SHANGHAI
111 Announces Changes to its Board of Directors SHANGHAI, May 16, 2019 111, Inc. (NASDAQ: YI) ( 111 or the Company ), a leading integrated online and offline healthcare platform, today announced that Dr. Leon Lian Yong Chen has been appointed as a new member to the board of dire
Read more →-YI
May 16, 2019Inc. Announces First Quarter 2019 Unaudited Financial Results SHANGHAI, CHINA May 16 , 2019 - 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today ann
111, Inc. Announces First Quarter 2019 Unaudited Financial Results SHANGHAI, CHINA May 16, 2019 - 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial results for the first qu
Read more →-YI
Mar 7, 2019Inc. Announces Fourth Quarter and Fiscal Year 2018 Unaudited Financial Results SHANGHAI, CHINA
111, Inc. Announces Fourth Quarter and Fiscal Year 2018 Unaudited Financial Results SHANGHAI, CHINA - March 7, 2019 - 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial resu
Read more →-YI
Feb 27, 2019Inc. Announces the Appointment of a New Chief Financial Officer
111, Inc. Announces the Appointment of a New Chief Financial Officer SHANGHAI, China, February 27, 2019 (GLOBE NEWSWIRE) - 111, Inc. (Nasdaq: YI) ( 111 or the Company ), a leading integrated online and offline healthcare platform, today announced that Mr. Yang Chen has been appo
Read more →-YI
Jan 18, 2019Inc. Announces Management and Board Changes
111, Inc. Announces Management and Board Changes SHANGHAI, China, Jan. 18, 2019 (GLOBE NEWSWIRE) 111, Inc. (NASDAQ: YI) ( 111 or the Company ), a leading integrated online and offline healthcare platform in China, today announced that Mr. Weihao Xu has resigned as Chief Financia
Read more →-YI
Nov 8, 2018Inc. Announces Third Quarter 2018 Unaudited Financial Results SHANGHAI, CHINA
111, Inc. Announces Third Quarter 2018 Unaudited Financial Results SHANGHAI, CHINA - November 8, 2018 - 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading integrated online and offline healthcare platform in China, today announced its unaudited financial results for the th
Read more →Competitive Position
How YI ranks across every disease it competes inCompetitive Position is a premium feature
See how YI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial